Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -14.78% | -10.62% | -9.41% | -9.58% | -2.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.78% | -10.62% | -9.41% | -9.58% | -2.77% |
| Cost of Revenue | -8.53% | -4.75% | -5.79% | -7.40% | -0.16% |
| Gross Profit | -16.55% | -12.27% | -10.44% | -10.20% | -3.48% |
| SG&A Expenses | -7.57% | -10.48% | -15.58% | -21.66% | -19.30% |
| Depreciation & Amortization | 0.00% | 0.00% | 1.19% | 3.75% | 6.46% |
| Other Operating Expenses | 124.26% | 220.86% | 267.99% | 292.35% | 43.32% |
| Total Operating Expenses | -12.67% | -12.56% | -18.46% | -20.99% | -20.59% |
| Operating Income | 11.26% | 13.78% | 23.67% | 27.20% | 29.28% |
| Income Before Tax | 15.80% | 15.18% | 23.15% | 28.35% | 18.44% |
| Income Tax Expenses | 26.23% | 26.38% | 36.54% | 26.33% | -123.24% |
| Earnings from Continuing Operations | 15.78% | 15.16% | 23.13% | 28.35% | 19.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.78% | 15.16% | 23.13% | 28.35% | 19.11% |
| EBIT | 11.26% | 13.78% | 23.67% | 27.20% | 29.28% |
| EBITDA | 11.31% | 13.97% | 24.35% | 28.06% | 30.14% |
| EPS Basic | 35.68% | 37.16% | 43.06% | 48.16% | 46.02% |
| Normalized Basic EPS | 28.11% | 32.25% | 39.68% | 44.30% | 50.61% |
| EPS Diluted | 35.68% | 37.16% | 43.12% | 48.20% | 46.04% |
| Normalized Diluted EPS | 28.11% | 32.25% | 39.68% | 44.30% | 50.61% |
| Average Basic Shares Outstanding | 28.96% | 33.76% | 34.29% | 37.19% | 45.87% |
| Average Diluted Shares Outstanding | 28.96% | 33.76% | 34.29% | 37.19% | 45.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
